EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
20 Dezembro 2023 - 9:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed
to developing and commercializing therapeutics to improve the lives
of patients with serious retinal diseases, today announced that Jay
S. Duker, M.D., President and Chief Executive Officer of EyePoint
Pharmaceuticals will present at the 42nd Annual J.P. Morgan
Healthcare Conference in San Francisco on Wednesday, January 10,
2024 at 10:30 a.m. PT/1:30 p.m. ET.
A webcast and subsequent archived replay of the
presentation may be accessed via the Investors section of the
Company website at www.eyepointpharma.com.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
clinical-stage company committed to developing and commercializing
therapeutics to help improve the lives of patients with serious
retinal diseases. The Company's pipeline leverages its proprietary
bioerodible Durasert E™ technology for sustained intraocular drug
delivery. The Company’s lead product candidate, EYP-1901, is an
investigational sustained delivery treatment for VEGF-mediated
retinal diseases combining vorolanib, a selective and
patent-protected tyrosine kinase inhibitor (TKI) with Durasert E™.
Additional pipeline programs include EYP-2301, a promising TIE-2
agonist, razuprotafib, f/k/a AKB-9778, formulated in Durasert E™ to
potentially improve outcomes in serious retinal diseases. The
proven Durasert® drug delivery technology has been safely
administered to thousands of patient eyes across four U.S. FDA
approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by
Equinox Sciences for the localized treatment of all ophthalmic
diseases.
Investors:Christina
TartagliaStern IRDirect:
212-698-8700christina.tartaglia@sternir.com
Media ContactAmy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024